News

Last week the Society of General Internal Medicine (@SocietyGIM) hosted it’s first “live twitter chat." No surprise, Dr. Joel Boggan (@JoelBoggan), a Duke GIM internist, checked in.

We are proud to announce a new promotion in DGIM! Bruce Peyser, MD, has been promoted to Full Professor. 

School of Medicine Office for Faculty Development has announced the next class in its ALICE program, a leadership development opportunity for mid-career women faculty in the School of Medicine. Seven participants in the next class are from the Department of Medicine.

The Collaboration Development Grant is offered to Duke faculty members who desire to collaborate with artists/faculty members in their own or different disciplines to undertake new artistic work. Proposals are due by Fri., March 10, by 4 p.m.

Robert J. Lefkowitz, MD, will present his research at the Department's Research Seminar Series at noon on Friday, Jan. 27, 2017 in Duke Hospital Room 2002. Dr. Lefkowitz will discuss G-Protein Coupled Receptors.

Catch up with the Duke Internal Medicine Residency Program by reading the weekly newsletter for Jan. 23, 2017.

Robert Lefkowitz, MD, and Howard Rockman, MD, are colleagues and collaborators. They recently sat down to talk about what they've learned in their long careers in biomedical research. Hear more from Dr. Lefkowitz at noon on Fri., Jan. 27, at Medicine Research Seminar.

The Wallace H. Coulter Endowment at Duke University provides funding to support collaborative translational research projects that involve co-investigators from the Department of Biomedical Engineering and a clinical department in the School of Medicine. Full applications are due by March 9, 2017, but applicants are strongly encouraged to submit a brief summary by January 2017.

This week the main results of a large NIH-funded trial on primary care-based interventions for osteoarthritis (OA), led by multiple GIM investigators, was published in Annals of Internal Medicine.

Endocrinologist Matthew Crowley and the Durham Veteran Affairs Evidence-based Synthesis Program (ESP) team spent roughly a year researching metformin’s benefits and its FDA “black box” warnings to publish a systematic literature review on whether the drug had any significant clinical trends related to their topic’s research questions.